Results 31 to 40 of about 1,404,058 (313)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background The Improving Population Outcomes for Renal Tumours of childhood (IMPORT) is a prospective clinical observational study capturing detailed demographic and outcome data on children and young people diagnosed with renal tumours in the United Kingdom and the Republic of Ireland.
Naomi Ssenyonga +56 more
wiley +1 more source
The Diagnostic Accuracy of Chest CT in the Detection of Tumor and Nodal Status in Non Small Cell Lung Carcinoma [PDF]
, 2003 At this time there is an increasing demand for an accurate pre operative staging in non small cell lung cancer. Chest Computed Tomography (CT) is one of the imaging modality of choice used for this purpose.
Busroh, I. (Ismid) +3 more
core +1 more source
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2018 Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD‐L1] expression on ≥50% of tumor cells).
L. Paz-Ares +21 more
semanticscholar +1 more source
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2020 BACKGROUND Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Yi-long Wu +23 more
semanticscholar +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives Osteosarcoma is a radioresistant tumor that may benefit from stereotactic body radiation therapy (SBRT) for locoregional control in metastatic/recurrent disease. We report institutional practice patterns, outcomes, toxicity, and failures in osteosarcoma patients treated with SBRT.
Jenna Kocsis +13 more
wiley +1 more source
The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer [PDF]
, 1921 IntroductionIt is unknown what type of interstitial lung disease (ILD) has high risk for chemotherapy-related exacerbation of ILD. We investigated the risk of exacerbation of ILD for patients with lung cancer with ILD.MethodsOne hundred nine patients ...
Kenmotsu, Hirotsugu +11 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Bone tumours present significant challenges for affected patients, as multimodal therapy often leads to prolonged physical limitations. This is particularly critical during childhood and adolescence, as it can negatively impact physiological development and psychosocial resilience.
Jennifer Queisser +5 more
wiley +1 more source
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Drugs in Context, 2022 Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti +10 more
doaj +1 more source
Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer [PDF]
, 2018 Lung cancer is the leading cause of death worldwide. The treatment choice for advanced stage of lung cancer may depend on histotype, performance status (PS), age, and comorbidities. In the present study, we focused on the effect of metronomic vinorelbine
Bruno, P +7 more
core +1 more source
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2019 BACKGROUND In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed ...
M. Hellmann +25 more
semanticscholar +1 more source